Filing search / Entero Therapeutics, Inc. / "Incentive" / Page 2

8-K

1bkxvqv56i3yn9

14 Mar 24

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

6:09am

8-K

EX-4.1

geh wbzuf

14 Mar 24

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

6:09am

8-K

EX-10.7

dfhfao8

14 Mar 24

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

6:09am

8-K

EX-2.1

vh50o7zt9qs

14 Mar 24

Latiglutenase is a potentially first-in-class oral biotherapeutic for the treatment of celiac disease

6:09am

424B5

gap18ux6 k654c9z51

4 Mar 24

Prospectus supplement for primary offering

5:29pm

8-K

EX-99.1

6gqb chlf7h2bks

14 Dec 23

First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

9:15am

S-8

abxfg9 lhgjdz0dscaa

21 Aug 23

Registration of securities for employees

4:06pm

S-8

n1poq

21 Aug 23

Registration of securities for employees

4:06pm

S-8

EX-5.1

43u5lz54hkql p031

21 Aug 23

Registration of securities for employees

4:06pm

424B4

q98fob

20 Jul 23

Prospectus supplement with pricing info

5:26pm